See more : Farglory Life Insurance Co., Ltd. (5859.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Vera Therapeutics, Inc. (VERA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vera Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Retail Value Inc. (RVIC) Income Statement Analysis – Financial Results
- California Resources Corporation (CRC) Income Statement Analysis – Financial Results
- Metrics in Balance N.V. (MLMIB.PA) Income Statement Analysis – Financial Results
- Black Rose Industries Limited (BLACKROSE.BO) Income Statement Analysis – Financial Results
- Opto Circuits (India) Limited (OPTOCIRCUI.NS) Income Statement Analysis – Financial Results
Vera Therapeutics, Inc. (VERA)
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 1.86M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | -846.00K | 176.00K | 251.00K | 509.00K |
| Gross Profit | 1.86M | 846.00K | -176.00K | -251.00K | -509.00K |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 78.23M | 68.99M | 22.48M | 45.21M | 7.29M |
| General & Administrative | 23.79M | 21.91M | 11.92M | 4.04M | 4.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.79M | 21.91M | 11.92M | 4.04M | 4.41M |
| Other Expenses | 0.00 | 1.85M | 1.79M | -1.08M | 0.00 |
| Operating Expenses | 102.01M | 90.90M | 34.40M | 49.25M | 11.70M |
| Cost & Expenses | 102.01M | 90.90M | 34.40M | 49.25M | 11.70M |
| Interest Income | 4.19M | 1.75M | 15.00K | 8.00K | 159.00K |
| Interest Expense | 0.00 | 992.00K | 20.00K | 166.00K | 51.00K |
| Depreciation & Amortization | 0.00 | -846.00K | 176.00K | 251.00K | 509.00K |
| EBITDA | -102.01M | -90.90M | -34.23M | -53.00M | -11.19M |
| EBITDA Ratio | -5,478.63% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -102.01M | -90.90M | -34.40M | -52.24M | -11.96M |
| Operating Income Ratio | -5,478.63% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.02M | 1.85M | 1.79M | -1.17M | 108.00K |
| Income Before Tax | -95.99M | -89.06M | -32.61M | -53.41M | -11.85M |
| Income Before Tax Ratio | -5,155.16% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K |
| Net Income | -95.99M | -89.06M | -32.61M | -53.41M | -11.85M |
| Net Income Ratio | -5,155.21% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.25 | -3.35 | -1.53 | -14.40 | -3.46 |
| EPS Diluted | -2.25 | -3.35 | -1.53 | -14.40 | -3.46 |
| Weighted Avg Shares Out | 42.71M | 26.57M | 21.28M | 3.71M | 3.42M |
| Weighted Avg Shares Out (Dil) | 42.71M | 26.57M | 21.28M | 3.71M | 3.42M |
Should You Buy Vera Therapeutics (VERA) Ahead of Earnings?
Strong Small-Cap Insider Buys: Q1 2023
Why Vera Therapeutics Stock Bolted Higher This Week
Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)
VERA Dips Despite Positive Data From IgA Nephropathy Study
Why Vera Stock Crashed 60% On Its 'Positive' Kidney Drug Update — And Chinook Popped
Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2022 Annual Meeting
Vera Therapeutics to Present at Upcoming Conferences in September 2022
Vera Therapeutics to Present at Upcoming Conferences in May 2022
Vera Therapeutics Selected to Present Interim Phase 2 Data for MAU868 to Treat BK Virus in Kidney Transplant Patients as Oral Late-Breaker at the American Transplant Congress 2022
Source: https://incomestatements.info
Category: Stock Reports